These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30257080)

  • 1. Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.
    Mentzel TQ; van der Snoek R; Lieverse R; Oorschot M; Viechtbauer W; Bloemen O; van Harten PN
    J Clin Psychiatry; 2018 Sep; 79(6):. PubMed ID: 30257080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders.
    Wong J; Pang T; Cheuk NKW; Liao Y; Bastiampillai T; Chan SKW
    Psychopharmacology (Berl); 2022 Nov; 239(11):3393-3420. PubMed ID: 36180741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clozapine efficacy in tardive dyskinesia in schizophrenic patients.
    Bassitt DP; Louzã Neto MR
    Eur Arch Psychiatry Clin Neurosci; 1998; 248(4):209-11. PubMed ID: 9810484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.
    Li CR; Chung YC; Park TW; Yang JC; Kim KW; Lee KH; Hwang IK
    World J Biol Psychiatry; 2009; 10(4 Pt 3):919-24. PubMed ID: 19995222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review.
    Pardis P; Remington G; Panda R; Lemez M; Agid O
    J Psychopharmacol; 2019 Oct; 33(10):1187-1198. PubMed ID: 31347436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clozapine Treatment of Olanzapine-induced Tardive Dyskinesia: A Case Report.
    Sangroula D; Virk I; Mohammad W; Kahn DA
    J Psychiatr Pract; 2017 Jan; 23(1):53-59. PubMed ID: 28072646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII.
    Mentzel CL; Bakker PR; van Os J; Drukker M; Matroos GE; Hoek HW; Tijssen MA; van Harten PN
    J Clin Psychiatry; 2017 Mar; 78(3):e279-e285. PubMed ID: 28199071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
    Witter DP; Holbert RC; Suryadevara U
    Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Response to Clozapine and Its Clinical Correlates in the Treatment of Tardive Movement Syndromes: A Naturalistic Observational Study in Patients With Psychotic Disorders.
    Lee D; Baek JH; Bae M; Choi Y; Hong KS
    J Clin Psychopharmacol; 2019; 39(6):591-596. PubMed ID: 31688397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
    Carbon M; Hsieh CH; Kane JM; Correll CU
    J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tardive dyskinesia, clozapine, and treatment response.
    Dalack GW; Becks L; Meador-Woodruff JH
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 May; 22(4):567-73. PubMed ID: 9682273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial.
    Diehl A; Reinhard I; Schmitt A; Mann K; Gattaz WF
    Eur Psychiatry; 2009 Jan; 24(1):33-40. PubMed ID: 18774276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.
    Wietholter JP; Sizemore J; Piechowski K
    Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
    Chan CH; Chan HY; Chen YC
    Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.